Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.54
-0.0500-1.93%
Post-market: 2.560.0240+0.94%19:56 EDT
Volume:25.66K
Turnover:65.85K
Market Cap:25.34M
PE:-0.58
High:2.62
Open:2.59
Low:2.51
Close:2.59
52wk High:19.35
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:0.27
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3427
EPS(LYR):-4.0377
ROE:-89.23%
ROA:-50.69%
PB:0.94
PE(LYR):-0.63

Loading ...

Atossa Therapeutics Inc expected to post a loss of $1.03 a share - Earnings Preview

Reuters
·
May 08

Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses

Reuters
·
May 08

Atossa presents preclinical (Z)-endoxifen data in Duchenne muscular dystrophy mouse models

Reuters
·
May 08

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 Operating Expenses USD 9.87 Million

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million

Reuters
·
May 08

Atossa Therapeutics shareholders approve reverse stock split authorization

Reuters
·
May 08

Atossa says Phase 2 KARISMA trial shows Endoxifen cuts mammographic breast density 19.3%

Reuters
·
May 06

Atossa Therapeutics Announces Publication of Karisma Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

THOMSON REUTERS
·
May 06

BRIEF-Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright Syndrome

Reuters
·
May 04

Atossa says FDA grants rare pediatric disease designation for (Z)-endoxifen in MAS

Reuters
·
May 04

Atossa Therapeutics - Co, Intas Pharmaceuticals, Jina Pharmaceuticals Agree Not to Challenge Specified Endoxifen-Related Patents - SEC Filing

THOMSON REUTERS
·
Apr 16

Atossa Therapeutics - Parties Agree to Seek Termination of Ptab Proceedings - SEC Filing

THOMSON REUTERS
·
Apr 16

Atossa Therapeutics - Two Endoxifen Patents Expected to Remain Issued and Enforceable - SEC Filing

THOMSON REUTERS
·
Apr 16

Atossa Therapeutics - on April 13, Co Entered Settlement Agreement to Resolve Endoxifen Patent Disputes - SEC Filing

THOMSON REUTERS
·
Apr 16

Atossa settles Endoxifen patent dispute with Intas, Jina Pharmaceuticals

Reuters
·
Apr 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 27

Atossa Therapeutics : H.c. Wainwright Adjusts Target Price to $25 to Reflect 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
Mar 26

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Mar 26

Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)

Reuters
·
Mar 26